{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:26:32Z","timestamp":1781760392783,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"am","delay-in-days":387,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.canrad.2018.05.002","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T10:23:16Z","timestamp":1549275796000},"page":"132-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma"],"prefix":"10.1016","volume":"23","author":[{"given":"L.","family":"Qu\u00e9ro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gilardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Fumagalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Guillerm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Bauduceau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.M.","family":"Kirova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hennequin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Brice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2018.05.002_bib0110","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2018.05.002_bib0115","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/sj.bmt.1704214","article-title":"Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma","volume":"32","author":"Kewalramani","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.canrad.2018.05.002_bib0120","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2018.05.002_bib0125","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1016\/j.ijrobp.2012.04.007","article-title":"Role of salvage radiation therapy for patients with relapsed or refractory Hodgkin lymphoma who failed autologous stem cell transplant","volume":"84","author":"Goda","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.05.002_bib0130","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1097\/JTO.0000000000000686","article-title":"Clinical trials integrating immunotherapy and radiation for non-small-cell lung cancer","volume":"10","author":"Daly","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2018.05.002_bib0135","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2018.05.002_bib0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2016.06.384","article-title":"Abscopal effect in patients with metastatic melanoma treated with checkpoint inhibitors (Anti-CTLA-4 and Anti-PD1): A retrospective analysis of a single institution","volume":"96","author":"Carvalho","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.05.002_bib0145","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2018.05.002_bib0150","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2016.05.014","article-title":"Toxicity of definitive and postoperative radiation following ipilimumab in non-small cell lung cancer","volume":"98","author":"Boyer","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canrad.2018.05.002_bib0155","first-page":"e5748","article-title":"Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies: three case reports","volume":"96","author":"Lu","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.canrad.2018.05.002_bib0160","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ijrobp.2017.01.063","article-title":"Tolerability and safety of thoracic radiation and immune checkpoint inhibitors among patients with lung cancer","volume":"98","author":"Ahmed","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.05.002_bib0165","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.ijrobp.2017.09.012","article-title":"Phase 2 5-arm trial of ipilimumab plus lung or liver stereotactic radiation for patients with advanced malignancies","volume":"99","author":"Welsh","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.05.002_bib0170","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2018.05.002_bib0175","doi-asserted-by":"crossref","first-page":"8523","DOI":"10.1200\/JCO.2017.35.15_suppl.8523","article-title":"Safety and feasibility of consolidation pembrolizumab following concurrent chemoradiation for unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN14-179","volume":"35","author":"Durm","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.05.002_bib0180","doi-asserted-by":"crossref","first-page":"037","DOI":"10.1093\/annonc\/mdx091.037","article-title":"Symptomatic pneumonitis in the irradiated lung after nivolumab: Three case studies","volume":"28","author":"Roengvoraphoj","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2018.05.002_bib0185","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.canrad.2018.05.002_bib0190","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdx115","article-title":"Nivolumab induced radiation recall pneumonitis after two years of radiotherapy","volume":"28","author":"Shibaki","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2018.05.002_bib0195","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1183\/13993003.01737-2017","article-title":"Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?","volume":"51","author":"Louvel","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.canrad.2018.05.002_bib0200","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.05.002_bib0205","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1634\/theoncologist.2017-0004","article-title":"FDA Approval summary: nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma","volume":"22","author":"Kasamon","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.canrad.2018.05.002_bib0210","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321818303950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321818303950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:28:51Z","timestamp":1761136131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321818303950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1278321818303950"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2018.05.002","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2018.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}